Very good point. Inspired by your comment, I took another look at the deal from two different angles:
Board Perspective - the loan that offsets the risk of stage 2 placement not being approved demonstrates that the whole deal was structured with a long-term commitment in mind. The 12-month term indicates that the Board was looking for a pathway to keep the project moving, rather than just focusing on the placement itself.
Hebang Perspective - before the deal was struck, AEV had been sitting around a $10M market cap for a while. A loan that represents a 30% ratio of the market cap? Normally, you'd expect a big player like Hebang to insist on demanding security on the asset. Their willingness to offer it as an unsecured loan for 12 months is quite telling. This is a strong signal of their confidence in the value of the company, beyond just targeting the project asset.
- Forums
- ASX - By Stock
- AEV
- Ann: Strategic Investment from Sichuan Hebang Biotechnology
Ann: Strategic Investment from Sichuan Hebang Biotechnology, page-227
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AEV (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.04M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 1.0¢ | $610 | 60.98K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 7056687 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 953426 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 7056687 | 0.010 |
5 | 2296000 | 0.009 |
3 | 804999 | 0.008 |
3 | 1400000 | 0.007 |
5 | 10755000 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 568650 | 1 |
0.012 | 2047093 | 7 |
0.013 | 894066 | 6 |
0.014 | 1239999 | 2 |
0.015 | 3350146 | 7 |
Last trade - 15.37pm 11/10/2024 (20 minute delay) ? |
Featured News
AEV (ASX) Chart |